Genetic Advances Made in Prostate Cancer Identification

Prostate cancer affects approximately 15 percent of males in their lifetime, and is second only to skin cancer. Recent identification of an overactive gene that accelerates prostate cancer could lead to development of a more effective treatment.

Prostate Cancer Evolves Beyond Drugs

Most prostate tumors are caused by a form of cancer called adenocarcinoma. In advanced stages, adenocarcinoma is treated with drugs that block androgens, the male hormones that fuel the tumor. Unfortunately, the tumors have evolved into a more aggressive, androgen-resistant form called neuroendocrine prostate cancer.

Prostate Cancer Identification
Prostate Cancer Identification

A cross-disciplinary team supported by the Prostate Cancer Foundation discovered a gene known as N-Myc that appears to be the driver behind the change to the more aggressive form. While N-Myc is not usually found in prostate cancer, it has been known to occur in other forms such as neuroblastoma, a rare cancer of the nervous system found in children.

A Pathway to New Treatment Methods

When N-Myc goes into overdrive, it teams up with a protein called EZH2 to block the tumor’s androgen signaling and “flips the switch” on the molecular program that leads to the more aggressive neuroendocrine form. Dr. Jonathan W. Simons, president and CEO of the Prostate Cancer Foundation, calls this a “game-changing” discovery that can enable development of more successful treatments.

Personalized, Non-Toxic Treatments for Prostate Cancer

Issels® offers a wide range of Immunotherapy for Cancer protocols, including vaccines and NK cells that have been used to treat patients with prostate cancer, melanoma, leukemia and all other forms. Contact us today to find out how Immunotherapy for Cancer at Issels® can help you or your loved one.

University Researchers Show How Wearable Technology Can Fight Cancer

Can Wearable Technology Change How Cancer is Fought?
Can Wearable Technology Change How Cancer is Fought?

Wearables like smartwatches and fitness trackers have been at the forefront of the latest wave of technology. Thanks to researchers at the University of Southern California, wearable technology could be the next step in more effective cancer treatment.

Cancer Moonshot Launches ATOM-HP

“South by South Lawn” (SXSL) is a White House-based festival patterned after the ground-breaking SXSW annual event in Austin, TX. SXSL gathers and celebrates innovators and visionaries who are creating ways to improve lives, both domestically and globally.

The USC project, called Analytical Technologies to Objectively Measure Human Performance (ATOM-HP), is part of the Cancer Moonshot initiative started by Vice President Joe Biden. ATOM-HP uses wearable devices to provide doctors with real-time data that was previously unavailable.

The ATOM-HP Difference

Even during cancer treatment, doctors and patients have only sporadic contact. Decisions are based on the doctor’s observations and self-reporting by the patient, which can result in an incomplete picture of the illness. ATOM-HP lets the doctor “see” effects of treatment and its impact on the patient’s everyday life.

As explained by Jorge Nieva, co-lead on ATOM-HP, the process humanizes treatment by allowing doctors to observe patients beyond the controlled confines of the hospital or clinic. Nieva refers to it as a “safety net for patients” who may be struggling with cancer treatments.

Co-lead Peter Kuhn stressed the importance of ATOM-HP for cancer research. Instead of relying on previously collected data, researchers will have the benefit of real-time information.

Personalized, Non-Toxic Immunotherapy for Cancer

At Issels®, we incorporate the most up-to-date technology and methods in our immunotherapy for cancer. Contact us today for more information.

Does Treatment Cause Cancer to Spread?

Can Cancer Treatment Causer The Spread of Cancer
Can Cancer Treatment Causer The Spread of Cancer

One of the obstacles to immunotherapy for cancer and other traditional treatments is that the disease can reoccur. While it was believed this was due to cancer cells developing resistance to drugs, recent evidence suggests that the problem may be the treatments themselves.

“A Double-Edged Sword”

Penicillin and other antibiotics were once hailed as “wonder drugs,” but overuse resulted in many forms of bacteria adapting and becoming immune to the toxic effects. The medical community felt the same process was behind the tendency of cancer to reoccur and spread to other areas.

A recent discovery by a team of Israeli scientists has shed new light on the problem. Their study involved mice with multiple myeloma, which is produced in bone marrow and spreads throughout the body. They received treatment with bortezomib, an anti-cancer drug with the brand name of Velcade.

The researchers were surprised to find that Velcade caused inflammatory cells in the bone marrow to accelerate the cancer, arming the cells with resistant properties. While they emphasize that “treatment with Velcade is essential and necessary,” the team is working on methods to inhibit the body’s response so treatments are more effective.

Immunotherapy for Cancer: A Personalized Approach

Our Issels® immunotherapy treatments are developed to meet each patient’s individual needs. These integrative programs attack cancer cells directly and treat the underlying causes to reduce the risk of tumor growth and reoccurrence.

Contact us to learn more about cancer vaccines, NK cells and the other non-toxic immunotherapy for cancer treatments offered at Issels®.